HK1222396A1 - 作為選擇性蛋白質激酶抑制劑之苯並咪唑衍生物 - Google Patents
作為選擇性蛋白質激酶抑制劑之苯並咪唑衍生物Info
- Publication number
- HK1222396A1 HK1222396A1 HK16110610.1A HK16110610A HK1222396A1 HK 1222396 A1 HK1222396 A1 HK 1222396A1 HK 16110610 A HK16110610 A HK 16110610A HK 1222396 A1 HK1222396 A1 HK 1222396A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- selective
- kinase inhibitors
- benzimidazole derivatives
- proteine kinase
- proteine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13305837 | 2013-06-20 | ||
PCT/EP2014/063045 WO2014202763A1 (en) | 2013-06-20 | 2014-06-20 | Benzimidazole derivatives as selective proteine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1222396A1 true HK1222396A1 (zh) | 2017-06-30 |
Family
ID=48741004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16110610.1A HK1222396A1 (zh) | 2013-06-20 | 2016-09-06 | 作為選擇性蛋白質激酶抑制劑之苯並咪唑衍生物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10202370B2 (zh) |
EP (1) | EP3010906B1 (zh) |
AR (1) | AR096654A1 (zh) |
HK (1) | HK1222396A1 (zh) |
TW (1) | TW201534597A (zh) |
WO (1) | WO2014202763A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
TW202128675A (zh) | 2019-12-06 | 2021-08-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑之經取代四氫呋喃 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US20230192626A1 (en) * | 2020-05-26 | 2023-06-22 | Baylor College Of Medicine | Novel soluble epoxide hydrolase inhibitors and method of use thereof |
CN115916777A (zh) * | 2020-07-09 | 2023-04-04 | 苏州爱科百发生物医药技术有限公司 | 一种atx抑制剂及其制备方法和应用 |
CN114380817A (zh) * | 2020-10-21 | 2022-04-22 | 中国医学科学院药物研究所 | 苯并咪唑并2-氨基-1,3,4-噻二唑化合物及其制法和药物用途 |
US11827627B2 (en) | 2021-06-04 | 2023-11-28 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
EP4367112A1 (en) | 2021-07-09 | 2024-05-15 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
WO2024017381A1 (zh) * | 2022-07-22 | 2024-01-25 | 深圳众格生物科技有限公司 | 一种抑制irak4活性的化合物及其应用 |
CN115850258A (zh) * | 2022-12-27 | 2023-03-28 | 东北林业大学 | 一种马赛替尼的合成方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
HRP970371A2 (en) * | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
FR2751649B1 (fr) * | 1996-07-26 | 1998-08-28 | Adir | Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
CN101328186A (zh) * | 1997-11-11 | 2008-12-24 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
BR0009721A (pt) * | 1999-04-15 | 2002-02-13 | Bristol Myers Squibb Co | Inibidores de tirosina quinase de proteìna cìclica |
ES2294344T3 (es) * | 2002-08-02 | 2008-04-01 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su utilizacion como inhibidores de c-kit. |
CA2523126A1 (en) * | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
AU2004268948A1 (en) * | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors |
KR20070118068A (ko) * | 2004-11-23 | 2007-12-13 | 레디 유에스 테라퓨틱스 인코포레이티드 | 신규의 이원 헤테로고리 화합물, 그 제조방법 및 이들을포함하는 조성물 |
EP1853606B1 (en) * | 2005-02-10 | 2008-11-19 | Smithkline Beecham Corporation | Pyridopyrazolopyrimidine compounds and their uses as anti-cancer and anti-diabete drugs |
WO2007081630A2 (en) * | 2005-12-21 | 2007-07-19 | Janssen Pharmaceutica, N.V. | Substituted pyrimidinyl kinase inhibitors |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
EP1878733A1 (en) * | 2006-07-14 | 2008-01-16 | Novartis AG | Pyrimidine derivatives as ALK-5 inhibitors |
DK2078010T3 (da) | 2006-12-29 | 2014-04-28 | Rigel Pharmaceuticals Inc | Polycyklisk heteroaryl-substituerede triazoler, der er anvendelige som axl-hæmmere |
WO2009063240A1 (en) * | 2007-11-16 | 2009-05-22 | Arrow Therapeutics Limited | 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase |
US20100311965A1 (en) * | 2007-12-28 | 2010-12-09 | Carna Biosciences Inc. | 2-aminoquinazoline derivative |
WO2009134754A1 (en) | 2008-04-28 | 2009-11-05 | Janssen Pharmaceutica Nv | Benzoimidazole glycinamides as prolyl hydroxylase inhibitors |
TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
EP2379529B1 (de) * | 2008-12-19 | 2015-06-10 | Boehringer Ingelheim International Gmbh | Cgrp-antagonisten |
WO2010106333A1 (en) * | 2009-03-19 | 2010-09-23 | Medical Research Council Technology | Compounds |
CN102459236B (zh) * | 2009-05-27 | 2014-10-29 | Abbvie公司 | 激酶活性的嘧啶抑制剂 |
US8927547B2 (en) | 2010-05-21 | 2015-01-06 | Noviga Research Ab | Pyrimidine derivatives |
KR20130141500A (ko) * | 2010-09-29 | 2013-12-26 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
EP2668177B1 (en) * | 2011-01-28 | 2014-10-22 | Boehringer Ingelheim International GmbH | Substituted pyridinyl-pyrimidines and their use as medicaments |
WO2012127032A1 (en) | 2011-03-24 | 2012-09-27 | Chemilia Ab | Novel pyrimidine derivatives |
TWI606049B (zh) * | 2011-04-21 | 2017-11-21 | 原真股份有限公司 | 新穎激酶抑制劑 |
-
2014
- 2014-06-19 AR ARP140102316A patent/AR096654A1/es unknown
- 2014-06-19 TW TW103121276A patent/TW201534597A/zh unknown
- 2014-06-20 EP EP14732550.0A patent/EP3010906B1/en active Active
- 2014-06-20 US US14/900,008 patent/US10202370B2/en active Active
- 2014-06-20 WO PCT/EP2014/063045 patent/WO2014202763A1/en active Application Filing
-
2016
- 2016-09-06 HK HK16110610.1A patent/HK1222396A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3010906B1 (en) | 2019-06-12 |
EP3010906A1 (en) | 2016-04-27 |
US20160152608A1 (en) | 2016-06-02 |
AR096654A1 (es) | 2016-01-27 |
TW201534597A (zh) | 2015-09-16 |
US10202370B2 (en) | 2019-02-12 |
WO2014202763A1 (en) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181429T8 (hr) | Novi derivati benzimidazola kao inhibitori kinaze | |
HK1222646A1 (zh) | 作為溴結構域抑制劑的苯並咪唑衍生物 | |
HK1220692A1 (zh) | 作為布羅莫結構域抑制劑的苯並咪唑酮衍生物 | |
HK1222396A1 (zh) | 作為選擇性蛋白質激酶抑制劑之苯並咪唑衍生物 | |
SG11201600062RA (en) | Pyrimidine derivatives as kinase inhibitors | |
ZA201406078B (en) | Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhibitors | |
EP2981535B8 (en) | Urea derivatives useful as kinase inhibitors | |
IL245660B (en) | History of aminopyridines as tam family kinase inhibitors | |
HK1211578A1 (zh) | 作為 激酶抑制劑的酰氨基咪唑並噠嗪 | |
HK1232227A1 (zh) | 作為 抑制劑的喹嗪酮衍生物 | |
HK1258911A1 (zh) | 可用作c-fms激酶抑制劑的取代的吡啶衍生物 | |
HK1213885A1 (zh) | 作為 抑制劑的咪唑並-三嗪衍生物 | |
EP2968324A4 (en) | SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS |